

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450

P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/002,603	10/30/2001	Alexander Gaiger	210121.465C6	3627
500 7590 04/08/2010 SEED INTELLECTUAL PROPERTY LAW GROUP PLLC			EXAMINER	
701 FIFTH AVE			SCHWADRON, RONALD B	
SUITE 5400 SEATTLE, W	A 98104 RE	CETVED	ART UNIT	PAPER NUMBER
,			1644	
	APR	1 2 2010		*
	SEED (ACTUAL)	ED INTELLECTUAL PROPERTY LAW GROUP PLLC	MAIL DATE	DELIVERY MODE
	LAW G		04/08/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Sequence Listing May 8, 2010

ENTERED IN DOCKE



SEED INTELLECTUAL PROPERTY LAW GROUP PLLC

701 FIFTH AVE SUITE 5400

SEATTLE, WA 98104

UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

P.O. Box 1450
Alexandria, Virginia 22313-1450

ER ET AL.

EXAMINER

Ron Schwadron, Ph.D.

ART UNIT PAPER

1644 201004

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Section <110> of the sequence listing in paper and CRF form does not list the correct applicants as per the Request to correct inventorship filed 9/29/09.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Ron Schwadron, Ph.D. Primary Examiner, Art Unit 1644 /Ron Schwadron/ Primary Examiner, Art Unit 1644

Notice to Comply

Application No.	Applicant(s)	_
10002603	GAIGER ET AL.	
Examiner	Art Unit	_
Ron Schwadron, Ph.D.	1644	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):					
 This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). 					
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).					
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).					
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."					
5. The computer readable form that has been filed with this applic unreadable as indicated on the attached CRF Diskette Problem R must be submitted as required by 37 C.F.R. 1.825(d).	eation has been found to be damaged and/or eport. A Substitute computer readable form				
6. The paper copy of the "Sequence Listing" is not the same as the Listing" as required by 37 C.F.R. 1.821(e).	e computer readable form of the "Sequence				
☑ 7. Other:					
Applicant Must Provide: ☑ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".					
An initial or substitute paper copy of the "Sequence Listing", as wits entry into the application.	well as an amendment specifically directing				
A statement that the content of the paper and computer reads include no new matter, as required by 37 C.F.R. 1.821(e) or 1.82	able copies are the same and, where applicable, 21(f) or 1.821(g) or 1.825(b) or 1.825(d).				
For questions regarding compliance to these requirements, please contact:					
For Rules Interpretation, call (571) 272-0731 or (571) 272-0951 For CRF Submission Help, call (571) 272-2510 Patentin Software Program Support Technical Assistance. 1-866-217-9197 or 703-305-3028 or 571-272-6845					
Patentin Software is Available At www.USPTO.gov					
PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY					